Viracta Therapeutics Inc (VIRX) Return on Investment ROI from the third quarter of 2024 to third quarter of 2023 and for the year 2024, average high and low, overall ranking from Sep 30 2024 to Sep 30 2023 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Viracta Therapeutics Inc   (NASDAQ: VIRX)


Viracta Therapeutics Inc's ROI from its third quarter of 2024 to the third quarter of 2023 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Viracta Therapeutics Inc's ROI in the third quarter of 2024?
Viracta Therapeutics Inc recorded a cumulative net loss of $-43 million during 12 months ending in the third quarter of 2024, resulting in a negative return on investment (ROI) of -341.35%.

Within the Healthcare sector 885 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the second quarter of 2024 from 4090 to 4646.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Sep 30 2024)
III. Quarter		 (Jun 30 2024)
II. Quarter		 (Mar 31 2024)
I. Quarter		 (Dec 31 2023)
IV. Quarter		 (Sep 30 2023)
III. Quarter
Y / Y Investment Change TTM -80.33 % -70.95 % -52.47 % -34.9 % -25.09 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions -7 3 11 44 30
Return On Investment (TTM) - -207.6 % -127.51 % -94.75 % -73.85 %
VIRX's Overall Ranking # 4646 # 4090 # 0 # 0 # 4319
Seq. Investment Change TTM -41.93 % -41.97 % -30.16 % -16.43 % -14.23 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -43 -45 -48 -51 -48

VIRX Company Profile >> Back to VIRX Roi Comparisons >> See Annual VIRX Return On Investment



Return On Investment VIRX's Ranking
Within: No.
Industry # 439
Sector # 886
Overall # 4646

Return On Investment Statistics
High Average Low
-94.64 %
-208.35 %
-566.65 %
(Dec 31 2023)   (Dec 31 2018)



  News about Viracta Therapeutics Inc Return on Investment ROI

Viracta Therapeutics Strategically Reassigns Resources to Bolster Nana-val Development Amid Organizational Restruct...

November 6, 2024

In a significant strategic pivot aimed at sharpening its developmental focus, Viracta Therapeutics has announced a realignment of resources that will prioritize its promising Nana-val program for patients grappling with relapsed or refractory Epstein-Barr Virus (EBV)-positive Peripheral T-Cell Lymphoma (PTCL). This decision underscores the company’s commitment to optimizing its research and development endeavors, particularly in addressing urgent therapeutic needs within oncology.The move towards a more robust commitment to the Nana-val program comes amidst a broader organizational restructuring that will see the company instituting a 42% reduction in its workforce. This reduction is not merely a cost-cutting exercise; instead, it reflects a strategic recalibration designed to focus efforts on advancing key programs that hold significant clinical promise. Furthermore, the Board of Directors is being resized from ten seats to six, reinforcing a streamlined governance structure that aligns with the company s newfound focus.





Financial Statements
Viracta Therapeutics Inc's III. Quarter Investments $ -7 Millions VIRX's Balance sheet
Viracta Therapeutics Inc's III. Quarter Income $ -11 Millions Quarterly VIRX's Income Statement
VIRX's Income by Division See VIRX's Income by Division


VIRX Annual Return On Investment (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021		 (Dec 31 2020)
2020		 (Dec 31 2019)
2019
Total Investments in Millions 18 86 99 20 28
Y / Y Investment Growth -78.69 % -13.32 % 397.52 % -28.35 % 595.43 %
Net Income in Millions -51 -49 0 -22 -23
Y / Y Net Income Growth - - - - -
Annual Return On Investment -278.72 % -57.22 % 0 % -108.39 % -83.85 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
VIRX's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for VIRX's Competitors
Subscribers only: Roi for Viracta Therapeutics Inc's Suppliers
Subscribers only: Return On Investment for VIRX's Customers

Other Ratios
VIRX's Roa VIRX's Inventory Turnover Ratio VIRX's Growth Rates VIRX's Dividend Statistics
VIRX's Profitability Ratios VIRX's Asset Turnover Ratio VIRX's Dividend Growth
VIRX's Roe VIRX's Valuation Ratios VIRX's Financial Strength Ratios VIRX's Dividend Payout Ratio



Companies with similar Return On Investment at Sep 30 2024, within Healthcare Sector ROI

Date modified: 2026-09-08T15:11:23+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.